



Book Supplement

Drug Treatment for HIV Infection and Side Effects

Agent	Notes
Zidovudine, ZDV (AZT; Retrovir®)	Nucleoside reverse transcriptase inhibitor. Side effects include: anemia, neutropenia, nausea, vomiting, headache, fatigue, confusion, malaise, myopathy, hepatopathy.
Didanosine, ddI (Videx®)	Nucleoside reverse transcriptase inhibitor. Side effects: peripheral neuropathy, pancreatitis, diarrhea, other GI disturbances.
Zalcitabine, ddC (Hivid®)	Nucleoside reverse transcriptase inhibitor. Side effects: neuropathy, rash, stomatitis, esophageal ulcers, pancreatitis, fever.
Stavudine, d4T (Zerit®)	Nucleoside reverse transcriptase inhibitor. Side effects: neuropathy; ascending neuromuscular weakness; less commonly hepatopathy, lactic acidosis, superficial fat atrophy, pancreatitis.
Lamivudine, 3TC (EpiVir®)	Nucleoside reverse transcriptase inhibitor. Side effects: generally well tolerated. Has anti-hepatitis B activity; therefore, hepatitis may flare up when discontinued.
Emtricitabine (FTC; Emtriva™)	Nucleoside reverse transcriptase inhibitor. Side effects: generally well tolerated; potential for lactic acidosis, fat distribution, and hepatotoxicity.
Abacavir (ABC; Ziagen™)	Nucleoside reverse transcriptase inhibitor. Side effects: hypersensitivity reaction (<i>with or without</i> rash, as fever may be the only sign of this reaction), which may result in shock or even death if rechallenge is attempted.
Nevirapine (Viramune®)	Non-nucleoside reverse transcriptase inhibitor. Side effects: rash (including Stevens-Johnson syndrome), fever, nausea, headache, drug-induced hepatitis.
Delavirdine (Rescriptor®)	Non-nucleoside reverse transcriptase inhibitor: Side effects: Occasional rash.
Efavirenz (EFV; Sustiva®)	Non-nucleoside reverse transcriptase inhibitor: Side effects: dizziness, insomnia or sleep disturbance, mood or psychiatric alterations, vivid dreams or hallucinations (CNS effects may diminish after first 2 weeks).

Saquinavir (hard gel capsule, Invirase®)	Protease inhibitor. Side effects: occasional GI upset or diarrhea. Hyperlipidemia, pancreatitis, fat redistribution, insulin resistance possible.
<u>Ritonavir</u> (Norvir®)	Protease inhibitor. Side effects: circumoral or peripheral paresthesias, nausea, vomiting, headache, diarrhea. Long-term associations include insulin resistance, fat redistribution, hyperlipidemia, and hepatopathy.
Nelfinavir (Viracept®)	Protease inhibitor. Side effects: Loose stools or diarrhea, which may improve over time. Reported long-term associations include hyperlipidemia, fat redistribution, insulin resistance.
Indinavir (Crixivan®)	Protease inhibitor. Side effects: Kidney stones, urethritis symptoms, hematuria, renal insufficiency, all attributed to crystallization of drug metabolite. Nausea, vomiting, headaches. Asymptomatic indirect hyperbilirubinemia and jaundice. Alopecia (especially body hair), dry skin, paronychia. Long-term associations with hyperlipidemia, fat redistribution, and insulin resistance reported.
Fosamprenavir (Lexiva™)	Protease inhibitor. Side effects: hyperglycemia, diarrhea, upset stomach, vomiting, headache, extreme tiredness, skin rash.
Atazanavir (Reyataz™)	Protease inhibitor. Side effects: Occasional nausea, abdominal pain, headache. Jaundice/scleral icterus may occur (similar to indinavir), but this is not a sign of hepatic toxicity.
Tipranavir (Aptivus®)	Protease inhibitor. Side effects: diarrhea, vomiting, nausea, hyperlipidemia, insulin resistance, fat redistribution, hepatotoxicity.
Tenofovir disoproxil fumarate (Viread™)	Acyclic nucleotide reverse transcriptase inhibitor. Side effects: generally well-tolerated; occasional nausea, diarrhea, asthenia, headache.
Enfuvirtide (T-20; Fuzeon™)	Inhibitor of membrane fusion step of viral entry into cells. Side effects: injection site reactions very common, typically local swelling and erythema, sometimes pruritus or mild pain. More severe reactions, sometimes with eosinophilia and signs of allergy, or cellulites have occurred occasionally. Unexplained trend towards more respiratory infections on T20-containing regimens.
Darunavir (Prezista™, TMC-114)	Protease inhibitor (indicated for patients with viral resistance to multiple protease inhibitors). Side effect profile comparable to other protease inhibitors.

Table from *Physicians Information and Education Resource (PIER)*, Human Immunodeficiency Virus module.